Skip to main content

Advertisement

SpringerLink
Log in

Could anti-HCV treatment prevent recurrence of hepatocellular carcinoma in HIV-infected patients? Two case reports

  • Brief Report
  • Published:
Infection Aims and scope Submit manuscript

Abstract

Highly active antiretroviral therapy (HAART) has proven long-term efficacy in human immunodeficiency virus (HIV) infection. Combination therapy with pegylated interferon and ribavirin has become the standard of care in patients with both hepatitis C virus (HCV) chronic hepatitis and HIV/HCV co-infection. Data on the safety and efficacy of combination therapy in chronic hepatitis C patients with hepatocellular carcinoma (HCC) is scarce and even more so in HIV/HCV co-infected subjects. We report the successful administration of both HAART and anti-HCV therapies in two HIV/HCV co-infected patients after HCC eradication. These encouraging results might argue for the feasibility of an aggressive approach in the management of co-infected patients with HCC.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Hogg RS, Heath KV, Yip B, et al. Improved survival among HIV-infected individuals following initiation of antiretroviral therapy. JAMA. 1998;279:450–4.

    Article  PubMed  CAS  Google Scholar 

  2. Palella FJ Jr, Delaney KM, Moorman AC, et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators. N Engl J Med. 1998;338:853–60.

    Article  PubMed  Google Scholar 

  3. Hogg RS, Yip B, Kully C, et al. Improved survival among HIV-infected patients after initiation of triple-drug antiretroviral regimens. CMAJ. 1999;160:659–65.

    PubMed  CAS  Google Scholar 

  4. Floridia M, Massella M, Bucciardini R, et al. Hospitalizations and costs of treatment for protease inhibitor-based regimens in patients with very advanced HIV-infection (CD4 < 50/mm3). HIV Clin Trials. 2000;1:9–16.

    Article  PubMed  CAS  Google Scholar 

  5. Mocroft A, Soriano V, Rockstroh J, et al.; EuroSIDA Study Group. Is there evidence for an increase in the death rate from liver-related disease in patients with HIV? AIDS. 2005;19,:2117–25.

    Article  PubMed  Google Scholar 

  6. Torriani FJ, Rodriguez-Torres M, Rockstroh JK, et al. Peginterferon Alfa-2a plus ribavirin for chronic hepatitis C virus infection in HIV-infected patients. N Engl J Med. 2004;351:438–50.

    Article  PubMed  CAS  Google Scholar 

  7. Soriano V, Puoti M, Sulkowski M, et al. Care of patients coinfected with HIV and hepatitis C virus: 2007 updated recommendations from the HCV-HIV International Panel. AIDS. 2007;21:1073–89.

    Article  PubMed  Google Scholar 

  8. European AIDS Clinical Society (EACS): Clinical management and treatment of chronic hepatitis B & C in HIV infected adults. 2009. http://www.europeanaidsclinicalsociety.org/images/stories/EACS-Pdf/3_chronic_hepatitis_b__c.pdf. Accessed 4 Sept 2011.

  9. Macdonald DC, Nelson M, Bower M, et al. Hepatocellular carcinoma, human immunodeficiency virus and viral hepatitis in the HAART era. World J Gastroenterol. 2008;14:1657–63.

    Article  PubMed  Google Scholar 

  10. Hino K, Okita K. Interferon therapy as chemoprevention of hepatocarcinogenesis in patients with chronic hepatitis C. J Antimicrob Chemother. 2004;53:19–22.

    Article  PubMed  CAS  Google Scholar 

  11. Heathcote EJ. Prevention of hepatitis C virus-related hepatocellular carcinoma. Gastroenterology. 2004;127(5 Suppl 1):S294–302.

    Article  PubMed  Google Scholar 

  12. Hung CH, Lee CM, Wang JH, et al. Antiviral therapy after non-surgical tumor ablation in patients with hepatocellular carcinoma associated with hepatitis C virus. J Gastroenterol Hepatol. 2005;20:1553–9.

    Article  PubMed  CAS  Google Scholar 

  13. Omata M, Yoshida H, Shiratori Y. Prevention of hepatocellular carcinoma and its recurrence in chronic hepatitis C patients by interferon therapy. Clin Gastroenterol Hepatol. 2005;3(10 Suppl 2):S141–3.

    Article  PubMed  CAS  Google Scholar 

  14. Italian Association for the Study of the Liver; Italian Society of Infectious, Tropical Diseases; Italian Society for the Study of Sexually Transmitted Diseases. Practice guidelines for the treatment of hepatitis C: recommendations from an AISF/SIMIT/SIMAST Expert Opinion Meeting. Dig Liver Dis. 2010;42:81–91.

    Article  Google Scholar 

  15. Huang JF, Yu ML, Huang CF, et al. The efficacy and safety of pegylated interferon plus ribavirin combination therapy in chronic hepatitis C patients with hepatocellular carcinoma post curative therapies—a multicenter prospective trial. J Hepatol. 2011;54:216–26.

    Article  Google Scholar 

  16. Befeler AS, Di Bisceglie AM. Hepatocellular carcinoma: diagnosis and treatment. Gastroenterology. 2002;122:1609–19.

    Article  PubMed  Google Scholar 

  17. Pineda JA, Romero-Gómez M, Díaz-García F, et al. HIV coinfection shortens the survival of patients with hepatitis C virus-related decompensated cirrhosis. Hepatology. 2005;41:779–89.

    Article  PubMed  Google Scholar 

  18. Puoti M, Bruno R, Soriano V, et al. Hepatocellular carcinoma in HIV-infected patients: epidemiological features, clinical presentation and outcome. AIDS. 2004;18:2285–93.

    Article  PubMed  Google Scholar 

  19. Bräu N, Fox RK, Xiao P, et al. Presentation and outcome of hepatocellular carcinoma in HIV-infected patients: a U.S.-Canadian multicenter study. J Hepatol. 2007;47:527–37.

    Article  PubMed  Google Scholar 

  20. García-Samaniego J, Rodríguez M, Berenguer J, et al. Hepatocellular carcinoma in HIV-infected patients with chronic hepatitis C. Am J Gastroenterol. 2001;96:179–83.

    PubMed  Google Scholar 

  21. Berretta M, Garlassi E, Cacopardo B, et al. Hepatocellular carcinoma in HIV-infected patients: check early, treat hard. Oncologist. 2011;16:1258–69.

    Article  PubMed  CAS  Google Scholar 

  22. Shiratori Y, Ito Y, Yokosuka O, et al. Antiviral therapy for cirrhotic hepatitis C: association with reduced hepatocellular carcinoma development and improved survival. Ann Intern Med. 2005;142:105–14.

    PubMed  CAS  Google Scholar 

  23. Ikeda K, Arase Y, Saitoh S, et al. Interferon beta prevents recurrence of hepatocellular carcinoma after complete resection or ablation of the primary tumor—a prospective randomized study of hepatitis C virus-related liver cancer. Hepatology. 2000;32:228–32.

    Article  PubMed  CAS  Google Scholar 

  24. Kubo S, Nishiguchi S, Hirohashi K, et al. Effects of long-term postoperative interferon-alpha therapy on intrahepatic recurrence after resection of hepatitis C virus-related hepatocellular carcinoma. A randomized, controlled trial. Ann Intern Med. 2001;134:963–7.

    PubMed  CAS  Google Scholar 

  25. Shiratori Y, Shiina S, Teratani T, et al. Interferon therapy after tumor ablation improves prognosis in patients with hepatocellular carcinoma associated with hepatitis C virus. Ann Intern Med. 2003;138:299–306.

    PubMed  Google Scholar 

  26. Lin SM, Lin CJ, Hsu CW, et al. Prospective randomized controlled study of interferon-alpha in preventing hepatocellular carcinoma recurrence after medical ablation therapy for primary tumors. Cancer. 2004;100:376–82.

    Article  PubMed  CAS  Google Scholar 

  27. Kubo S, Nishiguchi S, Hirohashi K, et al. Randomized clinical trial of long-term outcome after resection of hepatitis C virus-related hepatocellular carcinoma by postoperative interferon therapy. Br J Surg. 2002;89:418–22.

    Article  PubMed  CAS  Google Scholar 

  28. International Interferon-alpha Hepatocellular Carcinoma Study Group. Effect of interferon-alpha on progression of cirrhosis to hepatocellular carcinoma: a retrospective cohort study. Lancet. 1998;351:1535–9.

    Article  Google Scholar 

  29. Mazzaferro V, Romito R, Schiavo M, et al. Prevention of hepatocellular carcinoma recurrence with alpha-interferon after liver resection in HCV cirrhosis. Hepatology. 2006;44:1543–54.

    Article  PubMed  CAS  Google Scholar 

  30. Wright TL. Antiviral therapy and primary and secondary prevention of hepatocellular carcinoma. Hepatol Res. 2007;37(Suppl 2):S294–8.

    Article  PubMed  CAS  Google Scholar 

  31. Ishikawa T. Secondary prevention of recurrence by interferon therapy after ablation therapy for hepatocellular carcinoma in chronic hepatitis C patients. World J Gastroenterol. 2008;14:6140–4.

    Article  PubMed  CAS  Google Scholar 

  32. Abbas Z, Siddiqui AU, Luck NH, et al. Prognostic factors of survival in patients with non-resectable hepatocellular carcinoma: hepatitis C versus miscellaneous etiology. J Pak Med Assoc. 2008;58:602–7.

    PubMed  Google Scholar 

Download references

Conflict of interest

None.

Author information

Authors and Affiliations

  1. Department of Infectious Diseases, EO Ospedali Galliera, Via Volta 8, 16128, Genoa, Italy

    G. Cenderello, E. Pontali, G. Cassola & A. Torresin

Authors
  1. G. Cenderello
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. E. Pontali
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. G. Cassola
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. A. Torresin
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to E. Pontali.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Cenderello, G., Pontali, E., Cassola, G. et al. Could anti-HCV treatment prevent recurrence of hepatocellular carcinoma in HIV-infected patients? Two case reports. Infection 41, 199–202 (2013). https://doi.org/10.1007/s15010-012-0353-3

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s15010-012-0353-3

Keywords

Search

Navigation